Search CYAN
CYANOTECH CORP
OTC · CIK 768408
Last close0.41
Daily change+0.06 (17.14%)
10 Years gain-89.07%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CYAN · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 0331
Fundamental
15.6Momentum
99.1Acceleration
92.7Confidence
83.0Annual Revenue17
Quarterly Revenue67
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth3.0 / 25
Quality5.6 / 25
Capital Efficiency1.2 / 20
Balance Sheet3.6 / 15
Shareholder Economics2.2 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.2045 percentage points.
Operating leverageOperating margin improved by 9.8182 percentage points.
ROIC expansionROIC improved by 6.6017 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Low interest coverage · HIGHInterest coverage is -2.2335x.
Key Metrics
Revenue Growth TTM7.89%OK
Revenue CAGR 3Y-12.36%OK
Gross Margin31.53%OK
Operating Margin-6.4%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-9.34%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Mar 31, 2025 | $24.22M | $6.88M | -$2.51M | -$1.19M | n/a | 28.4% | -10.36% | n/a | -13.25% | n/a |
| 2025 FY Mar 31, 2024 | $23.07M | $5.95M | -$4.59M | -$455,000.00 | n/a | 25.77% | -19.9% | n/a | -19.93% | n/a |
| 2024 FY Mar 31, 2023 | $23.18M | $7.26M | -$2.92M | -$2.10M | n/a | 31.32% | -12.6% | n/a | -11.07% | 6,244 |
| 2024 FY Mar 31, 2022 | $35.97M | $13.57M | $2.57M | $2.38M | n/a | 37.72% | 7.16% | n/a | 12.31% | 6,168 |
| 2023 FY Mar 31, 2021 | $32.35M | $11.12M | $84,000.00 | $2.40M | n/a | 34.37% | 0.26% | n/a | 0.42% | 6.08M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $24.81M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-25-034093, 0001437749-25-003413 |
| Revenue Growth TTM | 7.89% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-25-034093, 0001437749-25-003413 |
| Revenue CAGR 3Y | -12.36% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-25-020904 |
| Revenue CAGR 5Y | -5.36% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-25-020904 |
| Gross Profit CAGR 3Y | -20.27% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001437749-25-020904 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-25-034093, 0001437749-25-003413 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 31.53% | Gross Profit / Revenue | OK | 0001437749-25-034093, 0001437749-25-003413 |
| Operating Margin | -6.4% | Operating Income / Revenue | OK | 0001437749-25-034093, 0001437749-25-003413 |
| ROIC | -9.34% | NOPAT / Average Invested Capital | OK | 0001437749-25-034093, 0001437749-25-003413 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-25-034093 |
| Interest Coverage | -2.23x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 1x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.15x | (Cash + Short-term Investments) / Total Debt | OK | 0001437749-25-034093 |